Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 15, 2010, Pages 4399-4405

  He, Shuwen ^a   Ye, Zhixiong ^a   Dobbelaar, Peter H ^a   Sebhat, Iyassu K ^a   Guo, Liangqin ^a   Liu, Jian ^a   Jian, Tianying ^a   Lai, Yingjie ^a   Franklin, Christopher L ^a   Bakshi, Raman K ^a   Dellureficio, James P ^a   Hong, Qingmei ^a   Weinberg, David H ^a   MacNeil, Tanya ^a   Tang, Rui ^a   Strack, Alison M ^a   Tamvakopoulos, Constantin ^a   Peng, Qianping ^a   Miller, Randy R ^a   Stearns, Ralph A ^a   Chen, Howard Y ^a   Chen, Airu S ^a   Fong, Tung M ^a   Wyvratt Jr , Matthew J ^a   Nargund, Ravi P ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Agonist; Amide; MC4R; Melanocortin subtype 4 receptor; MK 0489; Obesity; Privileged structure; Spiroindane

Indexed keywords

DEXFENFLURAMINE; MELANOCORTIN RECEPTOR AGONIST; MK 0489; SPIROINDANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; DIET; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; FOOD INTAKE; MOUSE; NONHUMAN; OBESITY; RAT; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; HUMANS; MICE; MICE, KNOCKOUT; OBESITY; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MELANOCORTIN, TYPE 4; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS; RODENTIA;

EID: 77955418066     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.06.062     Document Type: Article

References (35)

1. D.W. Haslam, and W.P. James Lancet 366 2005 1197
2. Obesity: Preventing and Managing the Global Epidemic, Report of a WHO Consultation, World Health Organization, Geneva, 2004.
3. H.E. Bays Obes. Res. 12 2004 1197
4. R.D. Cone Endocr. Rev. 27 2006 736
5. I. Gantz, and T.M. Fong Am. J. Physiol. Endocrinol. Metab. 284 2003 E468
6. Y.K. Yang, and C.M. Harmon Obes. Rev. 4 2003 239
7. D. Huszar, C.A. Lynch, V. Fairchild-Huntress, J.H. Dunmore, Q. Fang, L.R. Berkemeier, W. Gu, R.A. Kesterson, B.A. Boston, R.D. Cone, F.J. Smith, L.A. Campfield, P. Burn, and F. Lee Cell 88 1997 131
8. C. Vaisse, K. Clement, B. Guy-Grand, and P. Froguel Nat. Genet. 20 1998 113
9. G.S. Yeo, I.S. Farooqi, S. Aminian, D.J. Halsall, R.G. Stanhope, and S. O'Rahilly Nat. Genet. 20 1998 111
10. L.H.T. Van der Ploeg, W.J. Martin, A.D. Howard, R.P. Nargund, C.P. Austin, X. Guan, J. Drisko, D. Cashen, I. Sebhat, A.A. Patchett, D.J. Figueroa, A.G. DiLella, B.M. Connolly, D.H. Weinberg, C.P. Tan, O.C. Palyha, S.-S. Pong, T. MacNeil, C. Rosenblum, A. Vongs, R. Tang, H. Yu, A.W. Sailer, T.M. Fong, C. Huang, M.R. Tota, R.S. Chang, R. Stearns, C. Tamvakopoulos, G. Christ, D.L. Drazen, B.D. Spar, R.J. Nelson, and D.E. MacIntyre Proc. Natl. Acad. Sci. U.S.A. 99 2002 11381
11. M.E. Hadley Peptides 26 2005 1687
12. R.P. Nargund, A.M. Strack, and T.M. Fong J. Med. Chem. 49 2006 4035
13. F. Ujjainwalla, and I.K. Sebhat Curr. Top. Med. Chem. 7 2007 1068
14. I.K. Sebhat, W.J. Martin, Z. Ye, K. Barakat, R.T. Mosley, D.B.R. Johnston, R. Bakshi, B. Palucki, D.H. Weinberg, T. MacNeil, R.N. Kalyani, R. Tang, R.A. Stearns, R.R. Miller, C. Tamvakopoulos, A.M. Strack, E. McGowan, D.E. Cashen, J.E. Drisko, G.J. Hom, A.D. Howard, D.E. MacIntyre, L.H.T. van der Ploeg, A.A. Patchett, and R.P. Nargund J. Med. Chem. 45 2002 4589
15. B.L. Palucki, M.K. Park, R.P. Nargund, Z. Ye, I.K. Sebhat, P.G. Pollard, R.N. Kalyani, R. Tang, T. MacNeil, D.H. Weinberg, A. Vongs, C.I. Rosenblum, G.A. Doss, R.R. Miller, R.A. Stearns, Q. Peng, C. Tamvakopoulos, E. McGowan, W.J. Martin, J.M. Metzger, C.A. Shepherd, A.M. Strack, D.E. MacIntyre, L.H.T. Van der Ploeg, and A.A. Patchett Bioorg. Med. Chem. Lett. 15 2005 171
16. F. Ujjainwalla, D. Warner, C. Snedden, R.D. Grisson, T.F. Walsh, M.J. Wyvratt, R.N. Kalyani, T. MacNeil, R. Tang, D.H. Weinberg, L.H.T. van der Ploeg, and M.T. Goulet Bioorg. Med. Chem. Lett. 15 2005 4023
17. Ujjainwalla, F. Abstracts of Papers, Presentation (MEDI-275), 230th ACS National Meeting, Washington, DC, August 28-September 1, 2005.
18. L. Guo, Z. Ye, F. Ujjainwalla, H. Sings, I.K. Sebhat, J. Huber, D.H. Weinberg, R. Tang, T. McNeil, C. Tamvakopoulos, Q. Peng, E. MacIntyre, L.H.T. van der Ploeg, M.T. Goulet, M.J. Wyvratt, and R.P. Nargund Bioorg. Med. Chem. Lett. 18 2008 3242
19. S. He, Z. Ye, P.H. Dobbelaar, I.K. Sebhat, L. Guo, J. Liu, T. Jian, Y. Lai, C.L. Franklin, R.K. Bakshi, J.P. Dellureficio, Q. Hong, N.N. Tsou, R.G. Ball, D.E. Cashen, W.J. Martin, D.H. Weinberg, T. MacNeil, R. Tang, C. Tamvakopoulos, Q. Peng, R.R. Miller, R.A. Stearns, H.Y. Chen, A.S. Chen, A.M. Strack, T.M. Fong, D.E. MacIntyre, M.J. Wyvratt, and R.P. Nargund Bioorg. Med. Chem. Lett. 20 2010 2106
20. X. Tian, A.G. Switzer, S.A. Derose, R.K. Mishra, M.G. Solinsky, R.N. Mumin, F.H. Ebetino, L.R. Jayasinghe, M.E. Webster, A.-O. Colson, D. Crossdoersen, B.B. Pinney, J.A. Farmer, M.E. Dowty, C.M. Obringer, C.A. Cruze, M.L. Burklow, P.M. Suchanek, L. Dong, M.K. Dirr, R.J. Sheldon, and J.A. Wos J. Med. Chem. 51 2008 6055
21. X.W. Liu, J. Ma, A.-O. Colson, D.C. Doersen, and F.H. Ebetino Bioorg. Med. Chem. Lett. 18 2008 1223
22. C. Chen Prog. Med. Chem. 45 2007 111
23. C. Chen, W. Jiang, J.A. Tran, F.C. Tucci, B.A. Fleck, S. Markison, J. Wen, A. Madan, S.R. Hoare, A.C. Foster, D. Marinkovic, C.W. Chen, M. Arellano, and J. Saunders Bioorg. Med. Chem. Lett. 18 2008 129
24. C.G. Joseph, K.R. Wilson, M.S. Wood, N.B. Sorenson, D.V. Phan, Z. Xiang, R.M. Witek, and C. Haskell-Luevano J. Med. Chem. 51 2008 1423
25. S.L. Kuklish, R.T. Backer, K. Briner, C.W. Doecke, S. Husain, J.T. Mullaney, P.L. Ornstein, J.M. Zgombick, T.P. O'Brien, and M.F. Fisher Bioorg. Med. Chem. Lett. 16 2006 3843
26. In this communication, the lower case r or s in the compound number designates the R or S configuration at the stereogenic carbon of the spiroindane.
27. All data are mean values for at least three separate experiments. For a detailed description of the assay protocols, see.
28. M.A. Bednarek, T. MacNeil, R.N. Kalyani, R. Tang, L.H.T. Van der Ploeg, and D.H. Weinberg J. Med. Chem. 44 2001 3665
29. M.A. Bednarek, M.V. Siva, B. Arison, T. MacNeil, R.N. Kalyani, R.-R.C. Huang, and D.H. Weinberg Peptides 20 1999 401
30. C.P. Tan, K.K. McKee, D.H. Weinberg, T. MacNeil, O.C. Palyha, S.D. Feighner, D.L. Hreniuk, L.H.T. Van Der Ploeg, D.J. MacNeil, and A.D. Howard FEBS Lett. 451 1999 137
31. We were able to establish the R/S configuration analog 9r and 9s (see discussion later in the text).
32. 2 (0.5 mL) and treated with 4 M HCl in dioxane (2 mL) at rt. Upon completion of de-Boc, the mixture was concentrated in vacuo. The residue was dissolved in DMF (2 mL) and treated with N-methylmorpholine (NMM) (94 μL, 0.858 mmol), followed by HOAt (58 mg, 0.429 mmol), HATU (163 mg, 0.429 mmol) and acid 5 (49 mg, 0.172 mmol). The mixture was stirred overnight at rt. The mixture was then treated with 3,3-difluoroazetidine HCl salt (185 mg, 1.43 mmol) and NMM (314 μL, 2.86 mmol) at rt. Upon completion of reaction, the mixture was purified by reverse HPLC to give the analog 28s.
33. For a discussion of MC4R/3R knock out mouse, see: A.S. Chen, D.J. Marsh, M.E. Trumbauer, E.G. Frazier, X.-M. Guan, H. Yu, C.I. Rosenblum, A. Vongs, Y. Feng, L. Cao, J.M. Metzger, A.M. Strack, R.E. Camacho, T.N. Mellin, C.N. Nunes, W. Min, J. Fisher, S. Gopal-Truter, D.E. MacIntyre, H.Y. Chen, and L.H.T. Van der Ploeg Nat. Genet. 26 2000 97
34. 50) on mouse MC3R.
35. Control 1 was discovered previously in our laboratories. Ujjainwalla, F; Sings, H. L. unpublished results.